Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail (DDI)

NCT01784536 Phase 1 COMPLETED

The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.

Details

Lead sponsor	Melinta Therapeutics, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	16
Start date	2013-01
Completion	2013-03

Conditions

• Healthy

Interventions

• Single-Dose IV Oritavancin Diphosphate

Primary outcomes

• Change in the phenotyping measures of each probe drug in the absence and presence of oritavancin — Day 1 through Day 5

Countries

United States